Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 9,283 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
Interventions
Tagraxofusp, Azacitidine (AZA), Venetoclax
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
33
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 21 more
Conditions
Hepatic Impairment
Interventions
Telotristat Ethyl
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Conditions
Advanced Cancer
Interventions
LY2875358, LY2875358 + erlotinib, LY2875358 at Part A highest dose, LY2875358 at Part A highest dose + trametinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Conditions
Glioma
Interventions
M032
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Pancreatitis
Interventions
NI-03, Placebo
Drug
Lead sponsor
Kangen Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
28
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 24 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

NCT02208284
Conditions
Healthy
Interventions
PF-06427878, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methodology Issues in a Tailored Light Treatment for Persons With Dementia

NCT01816152
Conditions
Sleep Disturbances, Depression
Interventions
High Active intervention, Inactive intervention, Mid Level Active Intervention
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Albany, New York • New York, New York
Conditions
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
Interventions
MEDI3617, Bevacizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Lafayette, Indiana + 7 more
Conditions
Solid Tumor
Interventions
14C-labeled poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Migraine
Interventions
PF-05180999, Placebo, 120 mg MR PF-05180999, 360 mg MR PF-05180999, 10 mg cetirizine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
HIV Infections
Interventions
VSV-Indiana HIV gag vaccine, Placebo injection (normal saline)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
4
States / cities
San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more
Conditions
Lymphoma
Interventions
ofatumumab
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
48
States / cities
Lewes, Delaware • Newark, Delaware • Weston, Florida + 34 more
Conditions
Advanced Solid Tumors, Malignant Neoplasm
Interventions
MK-3120
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Birmingham, Alabama • Miami, Florida • Hackensack, New Jersey + 4 more
Conditions
Healthy Volunteers, Chronic Kidney Disease
Interventions
IGT-303, Placebo
Drug
Lead sponsor
Ingenia Therapeutics INC
Industry
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Chula Vista, California • Lakeland, Florida • Statesville, North Carolina + 1 more
Conditions
Solid Tumors
Interventions
JAB-30355
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • St Louis, Missouri + 4 more
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
JZP341
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Denver, Colorado • Sarasota, Florida • Baltimore, Maryland + 5 more
Conditions
Advanced Solid Tumors
Interventions
Treatment with ARQ 197 in combination with gemcitabine
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Atlanta, Georgia • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Conditions
Advanced Solid Tumor
Interventions
M9466, Irinotecan, Folinic acid, Fluorouracil (5-FU), Bevacizumab, Granulocyte colony stimulating factor (G-CSF)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Denver, Colorado • Pennington, New Jersey • Nashville, Tennessee + 1 more
Conditions
Neoplasms, Prostate
Interventions
GSK5471713
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Grand Rapids, Michigan + 2 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

NCT05827926
Conditions
SARS-CoV-2, Influenza
Interventions
Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,758 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
69
States / cities
Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more
Conditions
Advanced Solid Tumors
Interventions
ABI-011
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Conditions
Lymphoma
Interventions
apolizumab
Biological
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Freemont, California
Conditions
Bladder Cancer, Urinary Bladder Neoplasms
Interventions
MK-3120
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Bakersfield, California • New Brunswick, New Jersey • Myrtle Beach, South Carolina + 1 more